About: http://data.cimple.eu/news-article/92a72f0db2e1e078d73ecf3c72ab0168aab070b8394fed92bea2d7b3     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The European Medicines Agency is still reviewing the safety of a Covid-19 vaccine submitted by Pfizer and BionNTech and has not received clinical trial data, EU sources said Monday. A "rolling review" of several potential vaccines is underway and, for now, Brussels is sticking by its forecast that one may be approved and available "early next year", one source said. Earlier, the companies said that ongoing trials had found that their vaccine was 90 percent effective in preventing Covid-19 infections, sending hopes soaring for an end to the epidemic. The European Medicines Agency (EMA) has begun an expedited procedure to examine potential vaccines, and did nothing to pour cold water on reports of a breakthrough. But a spokeswoman for the Amsterdam-based agency said they had yet to receive the results of clinical trials. "Through rolling reviews, EMA can exceptionally evaluate data as it becomes available, ahead of a formal marketing-authorisation application," she said. "We evaluated the first batch of data on the vaccine, which came from laboratory studies (non-clinical data). "The agency is currently assessing a second batch of data which relate to the quality of the vaccine, including data related to its ingredients and the way it is produced. "Any new data available for this vaccine will be reviewed in the same way. We have not received nor assessed the emerging clinical data at this point and can therefore not comment further." Separately, in Brussels, a European source confirmed this and added "any prediction would be risky, but we have good indications that the first vaccine may be available early next year." European officials, including the president of the European Commission Ursula von der Leyen have previously used this timeline when talking about a future vaccine. And Brussels has put funding aside to reserve tens of millions of doses of future vaccines from several companies, including that from US giant Pfizer and its German partner BioNTech. jug-dk/dc/lc
schema:headline
  • EU still testing Pfizer vaccine, keeps 2021 forecast
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software